10,726 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTVFree Report) in the third quarter, HoldingsChannel.com reports. The fund bought 10,726 shares of the company’s stock, valued at approximately $166,000.

Several other institutional investors also recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $152,234,000. Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics in the third quarter valued at $7,435,000. Geode Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at $4,774,000. Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics during the third quarter worth about $4,506,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $2,912,000.

Artiva Biotherapeutics Stock Down 5.9 %

Artiva Biotherapeutics stock opened at $5.08 on Friday. Artiva Biotherapeutics, Inc. has a 12-month low of $4.77 and a 12-month high of $17.31. The company has a 50 day moving average of $9.68.

Artiva Biotherapeutics (NASDAQ:ARTVGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARTV has been the subject of several recent analyst reports. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $21.00.

Get Our Latest Report on ARTV

About Artiva Biotherapeutics

(Free Report)

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Featured Stories

Want to see what other hedge funds are holding ARTV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artiva Biotherapeutics, Inc. (NASDAQ:ARTVFree Report).

Institutional Ownership by Quarter for Artiva Biotherapeutics (NASDAQ:ARTV)

Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.